Abstract
Conclusions Resistance rates among common uropathogens continue to evolve and appear to be increasing to many commonly used agents. Continued surveillance of resistance rates among uropathogens is needed to ensure that appropriate recommendations can be made for treatment of infected patients. Further studies addressing the clinical and bacteriological outcomes of patients infected with a resistant pathogen are needed.